Amneal Pharma Secures FDA Approval For Additional Strengths And Vial Presentations Of Iohexol Injection; Co. Plans To Launch These Products In Q3 Of 2026
Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolioPortfolio now positioned to address the
Amneal got permission to sell more versions of a medicine that helps doctors see inside bodies during scans. This means the company can offer more choices to hospitals, which could help their business grow.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.